@AaronGoodman33 @dgermain21 Good point. But within indiv diseases, CD30 level does not correlate with activity. Sensible to try 1st in diseases which commonly express target. But when go broader, not to assume level of CD30 dictates response. Applies to ot
14,723 followers
9,309 followers
RT @graham74GC: Great work by my fantastic clinical fellow Stephen Booth. Phase I/IIa of HDACi CXD101 showing modest efficacy in T-cell & H…
2,454 followers
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma #lymphoma #lymsm https://t.co/eWgsZOy1Nk
14,723 followers
Great work by my fantastic clinical fellow Stephen Booth. Phase I/IIa of HDACi CXD101 showing modest efficacy in T-cell & Hodgkin lymphoma. No association of response with HR23B expression. #lymsm @EPCTU_Oxford @OxfordBRC @OUH_Research https://t.co